Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.
about
Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.Tuberculosis risk and anti-tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data.Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data.Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.Initiation of rheumatoid arthritis treatments and the risk of serious infections.74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission.A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesThe incidence of gastrointestinal perforations among rheumatoid arthritis patients.TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritisInfluence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations.The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsThe occurrence and prevention of foodborne disease in vulnerable people.Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry[How do register data support clinical decision-making?].Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analysesRisk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysisPhysicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System.Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.Tumor necrosis factor inhibitors and infection complications.Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.Treatment of severe psoriasis with infliximab.Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.Update on the use of etanercept across a spectrum of rheumatoid disorders.Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.Long-term use of adalimumab in the treatment of rheumatic diseases.
P2860
Q30009390-27C7725E-83B1-4AF6-AF57-A25FF23A8426Q30680371-E8A78370-386D-41EA-877A-2DF8EB82B9E7Q30799235-87890658-C40E-4D89-91C2-BE9EB8C191FCQ31148620-D11BD447-B8A4-41E9-B5F4-772A218A415DQ33778719-3C933244-B418-4BFA-B650-0D507697FA87Q33923452-C89BC4BA-6574-4277-A52A-74069453E795Q34019267-AB177BF2-0282-4490-BBC6-3A7128CE3160Q34027648-A3A522A0-904D-4269-8060-977F68B06C7DQ34081925-E0A1F871-EAC9-4459-8FA0-DE460C4E4E3FQ34154483-7F933CE2-30A2-406B-B95F-DC70C40F2876Q34216770-D46FF7DE-F156-4724-9FE8-F23F73EB3147Q34543316-32AC6CA3-50ED-4948-BA01-33DFD8DD2856Q34792330-33B14431-EFB2-43DA-A0B2-137003F73669Q34891374-BEAB5478-956D-4F8B-BE5F-0C78D56C52CCQ34984568-B1D5BE02-CDBC-4AE8-BC9D-0BF0CD1B7CECQ35026464-BACB2AC1-7842-4852-B15E-06C46FA7DED2Q35082559-536BAD6E-ABF9-4A43-BDDD-C9EC29E2E25DQ35173590-118F47AD-33DD-4DCE-B2D8-5AF40BC58FA6Q35249608-D780A490-A0AD-422E-B1E9-FDCCC481A713Q35258244-E6CEBC39-50D8-4A30-A7B6-5DD67A10A948Q35585867-C0A1E05F-7C10-4266-9B06-18229B272A70Q35617617-60CDF2E3-41AB-4999-BF96-55841C5E244FQ35617753-DF342744-2147-4816-B7C2-4968CB965247Q35636624-F132CAD6-C847-4C9D-8C39-DB124873C933Q35705082-7BA81D31-98B4-4488-8929-9A784480DC20Q35860042-D49DE6E4-5818-4C60-B3BD-8EC02A2B1C45Q35899264-2E7D08AE-3AB0-4FCE-8C71-415B6D681EB5Q36086443-355CE4C1-7E01-464F-A176-DC3B4923352BQ36150089-7AB4E58E-6C27-4219-A1C3-94EFFF2F1BBFQ36191250-C1B5F790-9387-4A17-B236-D797B7773933Q36806922-8BB479EC-0B5A-4D04-B15F-E8E5B07A547EQ36942914-9F472DE5-DCF4-480D-8EB7-0894E8FD8259Q37000165-68A7EA09-78A0-4C3C-B0A6-43EF16C04CD7Q37098135-619A954C-5C48-413C-BB1F-27CCE3C4EB73Q37189376-A915A9C1-0662-465E-B593-2AEC334967B2Q37235732-39C768D3-760B-495B-B313-18A39E812250Q37290628-6B46F691-15F6-474C-A769-9EC40FCCAE99Q37290665-A12DE4F1-F987-4F71-8F83-5FB0ED90CE67Q37330765-00A9FB96-FABF-4D74-8416-135D87039097Q37358124-69766629-BBBA-4FBD-9DAB-1D141740C71E
P2860
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Serious infection following an ...... ta from observational studies.
@ast
Serious infection following an ...... ta from observational studies.
@en
type
label
Serious infection following an ...... ta from observational studies.
@ast
Serious infection following an ...... ta from observational studies.
@en
prefLabel
Serious infection following an ...... ta from observational studies.
@ast
Serious infection following an ...... ta from observational studies.
@en
P2093
P2860
P50
P356
P1476
Serious infection following an ...... ata from observational studies
@en
P2093
A J Silman
British Society for Rheumatology Biologics Register Control Centre Consortium
British Society for Rheumatology Biologics Register
K D Watson
K L Hyrich
P2860
P304
P356
10.1002/ART.22808
P577
2007-09-01T00:00:00Z